---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Mechanism of action"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Mechanism of action. Topics: Antigen-binding fragment that selectively inhibits C1q, Nonproprietary name description: anti-C1q globular head region Fab, Binding to the substrate-binding head groups of C1q, Binding affinity and preservation of the lectin and alternative pathways, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Antigen-binding fragment that selectively inhibits C1q

> “Vonaprument is a clinical-stage investigational antigen-binding fragment (Fab) designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration.”
> “Vonaprument involves a differentiated neuroprotective approach designed to protect photoreceptor cells and retinal function by blocking C1q and the entire classical pathway, while allowing for normal immune activity of the lectin and alternative complement pathways.”

Source: [Annexon Biosciences Retina Society press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-present-patient-baseline-characteristics-vonaprument)

<a id="topic-2.1.2.6.1-2"></a>

### Nonproprietary name description: anti-C1q globular head region Fab

> “immunoglobulin Fab VH-G1(CH1-10h)_L-kappa, anti-[Homo sapiens C1q (complement C1q) globular head region], monoclonal antibody”
> “produced in Chinese hamster ovary (CHO) cells, non-glycosylated”
> “immunosuppressant, macular degeneration”

Source: [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)

<a id="topic-2.1.2.6.1-3"></a>

### Binding to the substrate-binding head groups of C1q

> “ANX007 is a novel high affinity monoclonal antibody antigen-binding fragment (Fab) that was designed to specifically recognize the substrate-binding head groups of C1q to functionally inhibit the classical complement cascade.”
> “The blockade of C1q prevents recruitment and activation of all downstream components within the classical pathway, including C4, C3, and C5, that drive a local immune response and tissue destruction in the retina.”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.1-4"></a>

### Binding affinity and preservation of the lectin and alternative pathways

> “ANX007 is an investigational, humanized antibody antigen-binding fragment that recognizes C1q and blocks its initiation of the classical complement pathway”
> “By selectively targeting C1q, ANX007 inhibits the classical pathway while leaving the lectin and alternative complement pathways intact for normal immune function and tissue homeostasis.”
> “ANX007 exhibits binding affinity for C1q (KD = 10 pM) and is a potent inhibitor of the classical complement cascade.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.1-5"></a>

### Product profile: 50 kD non-pegylated Fab with the anti-C1q structure of tanruprubart

> “Modeled on established IVT Fab antibodies”
> “Same anti-C1q structure as tanruprubart”
> “Small 50 kD Fab antibody”
> “Non-pegylated, with low viscosity and high potency (<10 pM)”
> “Full target engagement of classical pathway”
> “Lectin and alternative pathway left in place for immune and homeostatic functions”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.6.1-6"></a>

### Relationship to the full-length antibody ANX005

> “ANX007: non-pegylated IVT-administered Fab – fragment of ANX005”
> “C1q directly binds to synapses on stressed neurons, triggering elimination”

Source: [Lad (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Lad-MacSoc-2025-C1q-inhibition-GBS-HD-GA-.pdf)

<a id="topic-2.1.2.6.1-7"></a>

### Rationale for local C1q inhibition in geographic atrophy

> “Finally, C1q is locally produced within the retina during disease by infiltrating immune cells, indicating that its pathogenic role may be amenable to local inhibition of C1q.”
> “As described above, we believe inhibition of C1q would block all key components of the classical cascade, including C1q, C4, and C3 involved in immune cell attack and synapse pruning, as well as C5 involved in direct membrane damage.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.6.1-8"></a>

### Proposed differences from C3 and C5 inhibition

> “However, C3 and C5 inhibitors block the central and terminal aspects of all three complement pathways.”
> “In contrast, preventing the focused binding of C1q to its substrates would block all downstream classical cascade components and their amplification to reduce overall complement activation, while leaving the clearance and tissue repair functions of the lectin and alternative complement pathways in place.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
